Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel C Baumgart

Showing results (31-40 of 126) with videos related to

Pageof 13
Sort By:
Plos One|April 4, 2017
Tablet computer enhanced training improves internal medicine exam performanceDaniel C Baumgart, Ilja Wende, Ulrike Grittner
Gut|January 12, 2017
Vedolizumab safety in pregnancy and newborn outcomesMette Julsgaard, Jens Kjeldsen, Daniel C Baumgart
The Cochrane Database of Systematic Reviews|July 23, 2008
Tacrolimus (FK506) for induction of remission in refractory ulcerative colitisDaniel C Baumgart, John K Macdonald, Brian Feagan
Inflammatory Bowel Diseases|October 12, 2004
Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitisDaniel C Baumgart, Bertram Wiedenmann, Axel U Dignass
Recent Patents on Anti-Infective Drug Discovery|January 20, 2009
Management of severe abdominal infectionsDietrich Hasper, Joerg C Schefold, Daniel C Baumgart
Lancet (London, England)|June 9, 2026
Global advances in health artificial intelligence: a workforce imperativeTinglong Dai, Kathryn M McDonald, Daniel C Baumgart
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 12, 2020
Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and ManagementFerdinando D'Amico, Daniel C Baumgart, Silvio Danese, et al.
Frontiers in Pharmacology|April 16, 2019
Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?Daniel C Baumgart, Laurent Misery, Sue Naeyaert, et al.
Inflammatory Bowel Diseases|February 26, 2011
Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patientsDaniel C Baumgart, Ulrike Grittner, Andrea Steingräber, et al.
Gastrointestinal Endoscopy|March 11, 2005
Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuverDaniel C Baumgart, Wilfried Veltzke-Schlieker, Bertram Wiedenmann, et al.
Pageof 13

Showing results (31-40 of 126) with videos related to

Sort By:
Pageof 13
Plos One|April 4, 2017
Tablet computer enhanced training improves internal medicine exam performanceDaniel C Baumgart, Ilja Wende, Ulrike Grittner
Gut|January 12, 2017
Vedolizumab safety in pregnancy and newborn outcomesMette Julsgaard, Jens Kjeldsen, Daniel C Baumgart
The Cochrane Database of Systematic Reviews|July 23, 2008
Tacrolimus (FK506) for induction of remission in refractory ulcerative colitisDaniel C Baumgart, John K Macdonald, Brian Feagan
Inflammatory Bowel Diseases|October 12, 2004
Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus (FK506) in ulcerative colitisDaniel C Baumgart, Bertram Wiedenmann, Axel U Dignass
Recent Patents on Anti-Infective Drug Discovery|January 20, 2009
Management of severe abdominal infectionsDietrich Hasper, Joerg C Schefold, Daniel C Baumgart
Lancet (London, England)|June 9, 2026
Global advances in health artificial intelligence: a workforce imperativeTinglong Dai, Kathryn M McDonald, Daniel C Baumgart
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 12, 2020
Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and ManagementFerdinando D'Amico, Daniel C Baumgart, Silvio Danese, et al.
Frontiers in Pharmacology|April 16, 2019
Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?Daniel C Baumgart, Laurent Misery, Sue Naeyaert, et al.
Inflammatory Bowel Diseases|February 26, 2011
Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patientsDaniel C Baumgart, Ulrike Grittner, Andrea Steingräber, et al.
Gastrointestinal Endoscopy|March 11, 2005
Successful recanalization of a completely obliterated esophageal stricture by using an endoscopic rendezvous maneuverDaniel C Baumgart, Wilfried Veltzke-Schlieker, Bertram Wiedenmann, et al.
Pageof 13